New investors in gene therapy have missed the boat—the goose's golden eggs are gone
Share prices set to tumble...wonderful news, take heart!
Gene therapy has been a flop
In the post below, I predicted gene therapy products would be a flop once the shine wore off. Then, not too long ago, we heard the world’s largest contract development and manufacturing organisation (CDMO), Lonza, had fired its CEO on the back of reduced company earnings. Lonza manufactures the Moderna jab active ingredient, as those paying attention will know :O). Lonza’s share price dropped by 8% on the news!
This news was covered by TrialSite News, in an article titled:
This is an extract, where I got to have a say:
“Biotech supply chain expert Hedley Rees, a TrialSite contributor cautioned that the shakeup at Lonza is likely just the tip of the iceberg.
Keep reading with a 7-day free trial
Subscribe to INSIDE PHARMA to keep reading this post and get 7 days of free access to the full post archives.